NASDAQ:CASI

CASI Pharmaceuticals (CASI) Stock Price, News & Analysis

CASI Pharmaceuticals logo
$0.21 0.00 (0.00%)
As of 11/6/2026

About CASI Pharmaceuticals Stock (NASDAQ:CASI)

Advanced

Key Stats

Today's Range
$0.21
▼
$0.21
50-Day Range
$0.21
▼
$0.21
52-Week Range
$0.21
▼
$3.09
Volume
N/A
Average Volume
482,532 shs
Market Capitalization
$2.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines, particularly for cancer and blood disorders. Its commercial and development activities have been centered largely on China.

The company’s portfolio has included EVOMELA, a formulation of melphalan used in conditioning treatment for certain patients with multiple myeloma undergoing stem-cell transplantation. CASI has also pursued development and commercialization rights for additional oncology therapies, including CNCT19, an investigational CD19-directed CAR T-cell therapy.

CASI has built its business through product licensing and partnerships, working with other biotechnology companies to bring therapies to market and advance candidates in clinical development.

AI Generated. May Contain Errors.

Receive CASI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CASI Stock News Headlines

Your book is inside
Blane Markham and the Markham Trading Team are giving readers a limited window to download their options strategy guide, titled How To Turn $100 Options Into $1,000 Gains, before it moves behind a paywall. The guide walks through options trading concepts the team uses in its own research and education materials. Once the paywall goes up, free access ends for good.tc pixel
See More Headlines

CASI Stock Analysis - Frequently Asked Questions

CASI Pharmaceuticals' stock was trading at $0.85 at the beginning of 2026. Since then, CASI shares have decreased by 75.6% and is now trading at $0.2075.

CASI Pharmaceuticals Inc. (NASDAQ:CASI) posted its quarterly earnings data on Friday, November, 14th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by $0.27. The biotechnology company had revenue of $3.08 million for the quarter.

CASI Pharmaceuticals's stock reverse split on the morning of Wednesday, June 1st 2022.The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that CASI Pharmaceuticals investors own include Alibaba Group (BABA), AT&T (T), Tonix Pharmaceuticals (TNXP), Micron Technology (MU), NVIDIA (NVDA), Palantir Technologies (PLTR) and Aurora Cannabis (ACB).

Company Calendar

Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:CASI
CIK
1962738
Employees
180
Year Founded
1991

Profitability

EPS (Trailing Twelve Months)
($3.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$39.26 million
Net Margins
-183.93%
Pretax Margin
-175.56%
Return on Equity
N/A
Return on Assets
-131.54%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.30
Quick Ratio
0.24

Sales & Book Value

Annual Sales
$26.85 million
Price / Sales
0.10
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.12 per share
Price / Book
1.73

Miscellaneous

Outstanding Shares
12,299,000
Free Float
9,687,000
Market Cap
$2.55 million
Optionable
No Data
Beta
0.91

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:CASI) was last updated on 11/6/2026 by MarketBeat.com Staff.
From Our Partners